OBJECTIVE： To investigate the effectiveness and economics of 10 mg/d rosuvastatin and 20 mg/d atorvastatin in the treatment of hyperlipidemia （HLP）. METHODS： The information of 180 HLP patients selected from Tianmen Municipal First People’s Hospital during Mar. 2015-Feb. 2016 were divided into group A and B according to medication regimen， with 90 cases in each group. Group A was given Atorvastatin calcium tablet 20 mg， qd； group B was given Rosuvastatin calcium tablet 10 mg， qd. Treatment course of 2 groups lasted for 8 weeks. Blood lipid indexes before and after treatment， lipid-lowering efficacy， the rate of qualified blood lipid and the occurrence of ADR after treatment were compared between 2 groups. Cost-effectiveness analysis was adopted for economic evaluation. RESULTS： Before treatment， there was no statistical significance in the levels of blood lipid indexes between 2 groups （P＞0.05）. After treatment， TC and LDL-C levels of 2 groups were significantly lower than before treatment， and those of group B were significantly lower than those of group A， with statistical significance （P＜0.05）. Total response rate of lipid-lowering in group B （97.78％） was significantly higher than group A （86.67％）， and the rate of qualified blood lipid （66.67％） was also significantly higher than group A （51.11％）， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. The costs of group A and B were 488.32， 436.24 yuan， and cost-effectiveness ratios were 5.63， 4.46； incremental cost-effectiveness ratio was －4.69. The plan of group B had cost-effectiveness advantage. The results of cost-effectiveness analysis were supported by sensitivity analysis. CONCLUSIONS： In the view of short-term efficacy， 10 mg/d rosuvastatin plan is better than 20 mg/d atorvastatin plan in lowering lipid and has cost-effectiveness advantage， and both have similar safety.